FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Newell

Research Profile

Chemicals & Drugs

Anatomy

Concepts & Ideas

Co-author Network

Publications

TOP 3
Joanne M Munck; David R Newell; Caroline J Richardson; Andrew Slade; Graeme C M Smith; Michele Tavecchio; Pia Thommes; Yan Zhao; Jody Barbeau; Julia Bárdos; Michael A Batey; Celine Cano; Liam Cornell; Roger J Griffin; Helen Jenkins; Niall M B Martin; Keith A Menear; Nicola J Curtin
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.
Luis R de Brito; Andrew G Hall; Mike A Batey; Graham Jackson; Hing Y Leung; Helen Maitland; David R Newell; Matt S Squires; Yan Zhao; Julie A E Irving
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
S W Pridgeon; M Robinson; G A Taylor; Y-Z Xu; R Heer; P Karran; David R Newell; K O'Toole; Alan V Boddy
Thiothymidine combined with UVA as a potential novel therapy for bladder cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Newell (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Joanne M Munck; David R Newell; Caroline J Richardson; Andrew Slade; Graeme C M Smith; Michele Tavecchio; Pia Thommes; Yan Zhao; Jody Barbeau; Julia Bárdos; Michael A Batey; Celine Cano; Liam Cornell; Roger J Griffin; Helen Jenkins; Niall M B Martin; Keith A Menear; Nicola J Curtin
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.
Molecular cancer therapeutics 2012;11(8):1789-98.
2011: Luis R de Brito; Andrew G Hall; Mike A Batey; Graham Jackson; Hing Y Leung; Helen Maitland; David R Newell; Matt S Squires; Yan Zhao; Julie A E Irving
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Leukemia research 2011;35(9):1233-40.
2011: S W Pridgeon; M Robinson; G A Taylor; Y-Z Xu; R Heer; P Karran; David R Newell; K O'Toole; Alan V Boddy
Thiothymidine combined with UVA as a potential novel therapy for bladder cancer.
British journal of cancer 2011;104(12):1869-76.
2011: Kappusamy Saravanan; Hannah C Barlow; Marion Barton; A Hilary Calvert; Bernard T Golding; David R Newell; Julian S Northen; Nicola J Curtin; Huw D Thomas; Roger J Griffin
Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α1-acid glycoprotein.
Journal of medicinal chemistry 2011;54(6):1847-59.
2011: Ian R Hardcastle; Junfeng Liu; Eric Valeur; Anna Watson; Shafiq U Ahmed; Timothy J Blackburn; Karim Bennaceur; William Clegg; Catherine Drummond; Jane A Endicott; Bernard T Golding; Roger J Griffin; Jan Gruber; Karen Haggerty; Ross W Harrington; Claire Hutton; Stuart Kemp; Xiaohong Lu; James M McDonnell; David R Newell; Martin E M Noble; Sara L Payne; Charlotte H Revill; Christiane Riedinger; Qing Xu; John Lunec
Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
Journal of medicinal chemistry 2011;54(5):1233-43.
2010: Céline Cano; Olivier R Barbeau; Christine Bailey; Xiao-Ling Cockcroft; Nicola J Curtin; Heather Duggan; Mark Frigerio; Bernard T Golding; Ian R Hardcastle; Marc G Hummersone; Charlotte Knights; Keith A Menear; David R Newell; Caroline J Richardson; Graeme C M Smith; Ben Spittle; Roger J Griffin
DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype.
Journal of medicinal chemistry 2010;53(24):8498-507.
2010: Francesco Marchetti; Céline Cano; Nicola J Curtin; Bernard T Golding; Roger J Griffin; Karen Haggerty; David R Newell; Rachel J Parsons; Sara L Payne; Lan Z Wang; Ian R Hardcastle
Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors.
Organic & biomolecular chemistry 2010;8(10):2397-407.
2010: N Johnson; J Bentley; L-Z Wang; David R Newell; Craig N Robson; G I Shapiro; Nicola J Curtin
Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.
British journal of cancer 2010;102(2):342-50.
2009: Huw D Thomas; Kappusamy Saravanan; Lan-Zhen Wang; Mei-Ju Lin; Julian S Northen; Hannah Barlow; Marion Barton; David R Newell; Roger J Griffin; Bernard T Golding; Nicola J Curtin
Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity.
Molecular cancer therapeutics 2009;8(7):1828-37.
2009: Luke Harrison; Christopher J Ottley; D Graham Pearson; Céline Roche; Stephen R Wedge; M Eileen Dolan; David R Newell; Michael J Tilby
The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2.
Biochemical pharmacology 2009;77(10):1586-92.
2007: Alan V Boddy; Julieann Sludden; Melanie J Griffin; Colin Garner; John Kendrick; Pritesh Mistry; Catherine Dutreix; David R Newell; Stephen G O'Brien
Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4164-9.
2007: Francesco Marchetti; Kerry L Sayle; Johanne Bentley; William Clegg; Nicola J Curtin; Jane A Endicott; Bernard T Golding; Roger J Griffin; Karen Haggerty; Ross W Harrington; Veronique Mesguiche; David R Newell; Martin E M Noble; Rachel J Parsons; David J Pratt; Lan Z Wang; Ian R Hardcastle
Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2.
Organic & biomolecular chemistry 2007;5(10):1577-85.
2007: Jonathan J Hollick; Laurent Rigoreau; Celine Cano-Soumillac; Xiaoling Cockcroft; Nicola J Curtin; Mark Frigerio; Bernard T Golding; Sophie Guiard; Ian R Hardcastle; Ian Hickson; Marc G Hummersone; Keith A Menear; Niall M B Martin; Ian Matthews; David R Newell; Rachel Ord; Caroline J Richardson; Graeme C M Smith; Roger J Griffin
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
Journal of medicinal chemistry 2007;50(8):1958-72.
2007: Huw D Thomas; Christopher R Calabrese; Michael A Batey; Stacie Canan; Zdenek Hostomsky; Suzanne Kyle; Karen A Maegley; David R Newell; Donald J Skalitzky; Lan-Zhen Wang; Stephen E Webber; Nicola J Curtin
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
Molecular cancer therapeutics 2007;6(3):945-56.
2007: Claire L Graham-Cole; Huw D Thomas; Gordon A Taylor; David R Newell; Roger G Melton; Richard Hesp; Alan V Boddy
An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed.
Cancer chemotherapy and pharmacology 2007;59(2):197-206.
2006: Ian R Hardcastle; Shafiq U Ahmed; Helen Atkins; Gillian Farnie; Bernard T Golding; Roger J Griffin; Sabrina Guyenne; Claire Hutton; Per Kallblad; Stuart J Kemp; Martin S Kitching; David R Newell; Stefano Norbedo; Julian S Northen; Rebecca J Reid; K Saravanan; Henriëtte M G Willems; John Lunec
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.
Journal of medicinal chemistry 2006;49(21):6209-21.
2006: Yan Zhao; Huw D Thomas; Michael A Batey; Ian G Cowell; Caroline J Richardson; Roger J Griffin; A Hilary Calvert; David R Newell; Graeme C M Smith; Nicola J Curtin
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Cancer research 2006;66(10):5354-62.
2006: Roger J Griffin; Andrew Henderson; Nicola J Curtin; Aude Echalier; Jane A Endicott; Ian R Hardcastle; David R Newell; Martin E M Noble; Lan Z Wang; Bernard T Golding
Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
Journal of the American Chemical Society 2006;128(18):6012-3.
2005: Marzia Pennati; Allyson J Campbell; Maria Curto; Mara Binda; Yuzhu Cheng; Lan Z Wang; Nicola J Curtin; Bernard T Golding; Roger J Griffin; Ian R Hardcastle; Andrew Henderson; Nadia Zaffaroni; David R Newell
Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.
Molecular cancer therapeutics 2005;4(9):1328-37.
2005: E Ruth Plummer; Mark R Middleton; Christopher Jones; Anna Olsen; Ian Hickson; Peter McHugh; Geoffrey P Margison; Gail McGown; Mary R Thorncroft; Amanda J Watson; Alan V Boddy; A Hilary Calvert; Adrian L Harris; David R Newell; Nicola J Curtin
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3402-9.
2005: David R Newell
How to develop a successful cancer drug--molecules to medicines or targets to treatments?
European journal of cancer (Oxford, England : 1990) 2005;41(5):676-82.
2005: Ian R Hardcastle; Shafiq U Ahmed; Helen Atkins; A Hilary Calvert; Nicola J Curtin; Gillian Farnie; Bernard T Golding; Roger J Griffin; Sabrina Guyenne; Claire Hutton; Per Kallblad; Stuart J Kemp; Martin S Kitching; David R Newell; Stefano Norbedo; Julian S Northen; Rebecca J Reid; K Saravanan; Henriëtte M G Willems; John Lunec
Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.
Bioorganic & medicinal chemistry letters 2005;15(5):1515-20.
2005: Melissa L Fishel; David R Newell; Roger J Griffin; Richard Davison; Lan-Zhen Wang; Nicola J Curtin; Eleanor G Zuhowski; Kristen Kasza; Merrill J Egorin; Robert C Moschel; M Eileen Dolan
Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity.
The Journal of pharmacology and experimental therapeutics 2005;312(1):206-13.
2004: Jayashree G Tikhe; Stephen E Webber; Zdenek Hostomsky; Karen A Maegley; Anne Ekkers; Jianke Li; Xiao-Hong Yu; Robert Almassy; Robert A Kumpf; Theodore J Boritzki; Cathy Zhang; Christopher R Calabrese; Nicola J Curtin; Suzanne Kyle; Huw D Thomas; Lan-Zhen Wang; A Hilary Calvert; Bernard T Golding; Roger J Griffin; David R Newell
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.
Journal of medicinal chemistry 2004;47(22):5467-81.
2004: Nicola J Curtin; Hannah C Barlow; Karen J Bowman; A Hilary Calvert; Richard Davison; Bernard T Golding; Bing Huang; Peter J Loughlin; David R Newell; Peter G Smith; Roger J Griffin
Resistance-modifying agents. 11.(1) Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to alpha1-acid glycoprotein.
Journal of medicinal chemistry 2004;47(20):4905-22.
2004: Ian R Hardcastle; Christine E Arris; Johanne Bentley; F Thomas Boyle; Yuzhu Chen; Nicola J Curtin; Jane A Endicott; Ashleigh E Gibson; Bernard T Golding; Roger J Griffin; Philip Jewsbury; Jerome Menyerol; Veronique Mesguiche; David R Newell; Martin E M Noble; David J Pratt; Lan Z Wang; Hayley J Whitfield
N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2.
Journal of medicinal chemistry 2004;47(15):3710-22.
2004: David R Newell; J Silvester; C McDowell; SS Burtles
The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies.
European journal of cancer (Oxford, England : 1990) 2004;40(6):899-906.
2004: Nicola J Curtin; Lan-Zhen Wang; Anthie Yiakouvaki; Suzanne Kyle; Christine A Arris; Stacie S Canan Koch; Stephen E Webber; Barbara W Durkacz; Hilary Calvert; Zdenek Hostomsky; David R Newell
Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):881-9.
2004: Christopher R Calabrese; Robert Almassy; Stephanie Barton; Michael A Batey; A Hilary Calvert; Stacie S Canan Koch; Barbara W Durkacz; Zdenek Hostomsky; Robert A Kumpf; Suzanne Kyle; Jianke Li; Karen A Maegley; David R Newell; Elena Notarianni; Ian J Stratford; Donald J Skalitzky; Huw D Thomas; Lan-Zhen Wang; Stephen E Webber; Kaye J Williams; Nicola J Curtin
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
Journal of the National Cancer Institute 2004;96(1):56-67.
2003: Kerry L Sayle; Johanne Bentley; F Thomas Boyle; A Hilary Calvert; Yuzhu Cheng; Nicola J Curtin; Jane A Endicott; Bernard T Golding; Ian R Hardcastle; Philip Jewsbury; Veronique Mesguiche; David R Newell; Martin E M Noble; Rachel J Parsons; David J Pratt; Lan Z Wang; Roger J Griffin
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.
Bioorganic & medicinal chemistry letters 2003;13(18):3079-82.
2003: David R Newell; K M Searle; N B Westwood; SS Burtles
Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.
British journal of cancer 2003;89(3):437-54.
2003: David R Newell
The drug development process: from target discovery to the clinic.
Clinical medicine (London, England) 2003;3(4):323-6.
2003: Christopher R Calabrese; Michael A Batey; Huw D Thomas; Barbara W Durkacz; Lan-Zhen Wang; Suzanne Kyle; Donald J Skalitzky; Janke Li; Catherine Zhang; Theodore J Boritzki; Karen A Maegley; A Hilary Calvert; Zdenek Hostomsky; David R Newell; Nicola J Curtin
Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2711-8.
2003: Paula Wells; Eric O Aboagye; Roger Gunn; Safiye Osman; Alan V Boddy; Gordon A Taylor; Imran Rafi; Andrew N Hughes; A Hilary Calvert; Patricia M Price; David R Newell
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.
Journal of the National Cancer Institute 2003;95(9):675-82.
2003: Veronique Mesguiche; Rachel J Parsons; Christine E Arris; Johanne Bentley; F Thomas Boyle; Nicola J Curtin; Thomas G Davies; Jane A Endicott; Ashleigh E Gibson; Bernard T Golding; Roger J Griffin; Philip Jewsbury; Louise N Johnson; David R Newell; Martin E M Noble; Lan Z Wang; Ian R Hardcastle
4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.
Bioorganic & medicinal chemistry letters 2003;13(2):217-22.
2003: Donald J Skalitzky; Joseph T Marakovits; Karen A Maegley; Anne Ekker; Xiao-Hong Yu; Zdenek Hostomsky; Stephen E Webber; Brian W Eastman; Robert Almassy; Jianke Li; Nicola J Curtin; David R Newell; A Hilary Calvert; Roger J Griffin; Bernard T Golding
Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.
Journal of medicinal chemistry 2003;46(2):210-3.
2002: Stacie S Canan Koch; Lars H Thoresen; Jayashree G Tikhe; Karen A Maegley; Robert Almassy; Jianke Li; Xiao-Hong Yu; Scott E Zook; Robert A Kumpf; Cathy Zhang; Theodore J Boritzki; Rena N Mansour; Kanyin E Zhang; Anne Ekker; Christopher R Calabrese; Nicola J Curtin; Suzanne Kyle; Huw D Thomas; Lan-Zhen Wang; A Hilary Calvert; Bernard T Golding; Roger J Griffin; David R Newell; Stephen E Webber; Zdenek Hostomsky
Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.
Journal of medicinal chemistry 2002;45(23):4961-74.
2002: Thomas G Davies; Johanne Bentley; Christine E Arris; F Thomas Boyle; Nicola J Curtin; Jane A Endicott; Ashleigh E Gibson; Bernard T Golding; Roger J Griffin; Ian R Hardcastle; Philip Jewsbury; Louise N Johnson; Veronique Mesguiche; David R Newell; Martin E M Noble; Julie A Tucker; Lan Wang; Hayley J Whitfield
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
Nature structural biology 2002;9(10):745-9.
2002: Ashleigh E Gibson; Christine E Arris; Johanne Bentley; F Thomas Boyle; Nicola J Curtin; Thomas G Davies; Jane A Endicott; Bernard T Golding; Sharon Grant; Roger J Griffin; Philip Jewsbury; Louise N Johnson; Veronique Mesguiche; David R Newell; Martin E M Noble; Julie A Tucker; Hayley J Whitfield
Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.
Journal of medicinal chemistry 2002;45(16):3381-93.
2002: Noel Monks; David C Blakey; Simon J East; Robert I Dowell; Joanne A Calvete; Nicola J Curtin; Christine E Arris; David R Newell
DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767.
European journal of cancer (Oxford, England : 1990) 2002;38(11):1543-52.
2002: Michael A Batey; J G Wright; Ashraf Azzabi; David R Newell; Michael Lind; A Hilary Calvert; Alan V Boddy
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
European journal of cancer (Oxford, England : 1990) 2002;38(8):1081-9.
2002: T R Cressey; Michael J Tilby; David R Newell
Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines.
European journal of cancer (Oxford, England : 1990) 2002;38(4):586-93.
2002: Huw D Thomas; David J Porter; Imke Bartelink; Joy R Nobbs; Michael Cole; Suzie Elliott; David R Newell; A Hilary Calvert; Martin Highley; Alan V Boddy
Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.
British journal of clinical pharmacology 2002;53(1):83-91.
2001: Noel Monks; David C Blakey; Nicola J Curtin; Simon J East; A Heuze; David R Newell
Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.
British journal of cancer 2001;85(5):764-71.
2001: Gareth Veal; C Dias; Lisa Price; Annie Parry; Julie Errington; Juliet Hale; Andrew D J Pearson; Alan V Boddy; David R Newell; Michael J Tilby
Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2205-12.
2001: X Lu; Julie Errington; Nicola J Curtin; John Lunec; David R Newell
The impact of p53 status on cellular sensitivity to antifolate drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):2114-23.
2001: Peter G Smith; Huw D Thomas; Hannah C Barlow; Roger J Griffin; Bernard T Golding; A Hilary Calvert; David R Newell; Nicola J Curtin
In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):2105-13.
2001: E Marshman; G A Taylor; Huw D Thomas; David R Newell; Nicola J Curtin
Hypoxanthine transport in human tumour cell lines: relationship to the inhibition of hypoxanthine rescue by dipyridamole.
Biochemical pharmacology 2001;61(4):477-84.
2001: Karen J Bowman; David R Newell; A Hilary Calvert; Nicola J Curtin
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
British journal of cancer 2001;84(1):106-12.
2001: EJ Estlin; C Ross Pinkerton; Ian J Lewis; Linda S Lashford; Heather McDowell; Bruce Morland; J Kohler; David R Newell; Alan V Boddy; Gordon A Taylor; L Price; S Ablett; Rachel Hobson; M Pitsiladis; MH Brampton; NJ Clendeninn; A Johnston; Andrew D J Pearson
A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation.
British journal of cancer 2001;84(1):11-8.
2000: Alex W White; Robert Almassy; A Hilary Calvert; Nicola J Curtin; Roger J Griffin; Zdenek Hostomsky; Karen A Maegley; David R Newell; S Srinivasan; Bernard T Golding
Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.
Journal of medicinal chemistry 2000;43(22):4084-97.
2000: Roger J Griffin; Christine E Arris; Christine Bleasdale; F Thomas Boyle; A Hilary Calvert; Nicola J Curtin; C Dalby; S Kanugula; N K Lembicz; David R Newell; A E Pegg; Bernard T Golding
Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine.
Journal of medicinal chemistry 2000;43(22):4071-83.
2000: H Thomas; Alan V Boddy; Martin W English; Rachel Hobson; John Imeson; Ian Lewis; Bruce Morland; Andrew D J Pearson; Ross Pinkerton; L Price; M Stevens; David R Newell
Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(21):3614-21.
2000: Christine E Arris; F Thomas Boyle; A Hilary Calvert; Nicola J Curtin; Jane A Endicott; E F Garman; Ashleigh E Gibson; Bernard T Golding; S Grant; Roger J Griffin; Philip Jewsbury; Louise N Johnson; AM Lawrie; David R Newell; Martin E M Noble; Edward A Sausville; R Schultz; W Yu
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Journal of medicinal chemistry 2000;43(15):2797-804.
2000: C A Delaney; Lan-Zhen Wang; Suzanne Kyle; Alex W White; A Hilary Calvert; Nicola J Curtin; Barbara W Durkacz; Zdenek Hostomsky; David R Newell
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2860-7.
2000: Noel Monks; J A Calvete; Nicola J Curtin; David C Blakey; Simon J East; David R Newell
Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT).
British journal of cancer 2000;83(2):267-9.
2000: Andrew N Hughes; Melanie J Griffin; David R Newell; A Hilary Calvert; A Johnston; B Kerr; C Lee; B Liang; Alan V Boddy
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel.
British journal of cancer 2000;82(9):1519-27.
2000: Hannah C Barlow; Karen J Bowman; Nicola J Curtin; A Hilary Calvert; Bernard T Golding; Bing Huang; Peter J Loughlin; David R Newell; Peter G Smith; Roger J Griffin
Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha1-acid glycoprotein (AGP).
Bioorganic & medicinal chemistry letters 2000;10(6):585-9.
2000: M J Barnes; Gordon A Taylor; David R Newell
Development of a whole cell assay to measure methotrexate-induced inhibition of thymidylate synthase and de novo purine synthesis in leukaemia cells.
Biochemical pharmacology 2000;59(4):321-8.
2000: Peter G Smith; E Marshman; David R Newell; Nicola J Curtin
Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport.
British journal of cancer 2000;82(4):924-30.
2000: X Lu; Julie Errington; V J Chen; Nicola J Curtin; Alan V Boddy; David R Newell
Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):271-7.
1999: David R Newell; SS Burtles; B W Fox; D I Jodrell; T A Connors
Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
British journal of cancer 1999;81(5):760-8.
1999: M J Barnes; EJ Estlin; Gordon A Taylor; G Wynne Aherne; Anthea Hardcastle; J J McGuire; JA Calvete; John Lunec; Andrew D J Pearson; David R Newell
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2548-58.
1999: Nicola J Curtin; Karen J Bowman; R N Turner; Bing Huang; Peter J Loughlin; A Hilary Calvert; Bernard T Golding; Roger J Griffin; David R Newell
Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.
British journal of cancer 1999;80(11):1738-46.
1999: David R Newell
Clinical pharmacokinetics of antitumor antifolates.
Seminars in oncology 1999;26(2 Suppl 6):74-81.
1999: Peter G Smith; E Marshman; A Hilary Calvert; David R Newell; Nicola J Curtin
Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
Seminars in oncology 1999;26(2 Suppl 6):63-7.
1999: Andrew N Hughes; Imran Rafi; Melanie J Griffin; A Hilary Calvert; David R Newell; JA Calvete; A Johnston; NJ Clendeninn; Alan V Boddy
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(1):111-8.
1998: Roger J Griffin; S Srinivasan; K Bowman; A Hilary Calvert; Nicola J Curtin; David R Newell; L C Pemberton; Bernard T Golding
Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).
Journal of medicinal chemistry 1998;41(26):5247-56.
1998: E Marshman; David R Newell; A Hilary Calvert; A M Dickinson; H R Patel; Frederick Charles Campbell; Nicola J Curtin
Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2895-902.
1998: Mark R Middleton; J M Lunn; C Morris; Gordon J S Rustin; SR Wedge; MH Brampton; Michael Lind; SM Lee; David R Newell; NM Bleehen; Edward S Newlands; A Hilary Calvert; Geoffrey P Margison; Nick Thatcher
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
British journal of cancer 1998;78(9):1199-202.
1998: EJ Estlin; Linda S Lashford; S Ablett; L Price; R Gowing; A Gholkar; J Kohler; Ian J Lewis; Bruce Morland; C Ross Pinkerton; M C Stevens; M Mott; R Stevens; David R Newell; D Walker; C Dicks-Mireaux; Heather McDowell; P Reidenberg; Paul Statkevich; A Marco; Vijay K Batra; Margaret Dugan; Andrew D J Pearson
Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.
British journal of cancer 1998;78(5):652-61.
1998: S P Lowis; Lisa Price; Andrew D J Pearson; David R Newell; M Cole
A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children.
British journal of cancer 1998;77(12):2318-23.
1998: Imran Rafi; Alan V Boddy; JA Calvete; Gordon A Taylor; David R Newell; N P Bailey; Michael Lind; M Green; J Hines; A Johnstone; NJ Clendeninn; A Hilary Calvert
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):1131-41.
1997: B Peng; Martin W English; Alan V Boddy; Lisa Price; RA Wyllie; Andrew D J Pearson; Michael J Tilby; David R Newell
Cisplatin pharmacokinetics in children with cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(11):1823-8.
1997: EJ Estlin; K Balmanno; A H Calvert; A G Hall; John Lunec; David R Newell; Andrew D J Pearson; Gordon A Taylor
The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ in human leukaemia and colorectal carcinoma cell lines.
British journal of cancer 1997;76(12):1579-85.
1997: B Peng; Michael J Tilby; Martin W English; Lisa Price; Andrew D J Pearson; Alan V Boddy; David R Newell
Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
British journal of cancer 1997;76(11):1466-73.
1996: S P Lowis; David R Newell
Etoposide for the treatment of paediatric tumours: what is the best way to give it?
European journal of cancer (Oxford, England : 1990) 1996;32A(13):2291-7.
1996: S Ghazal-Aswad; L Hogarth; Andrew G Hall; M George; D P Sinha; M Lind; A Hilary Calvert; J P Sunter; David R Newell
The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients.
British journal of cancer 1996;74(3):468-73.
1996: Martin W English; S P Lowis; B Peng; Alan V Boddy; David R Newell; Lisa Price; Andrew D J Pearson
Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis.
British journal of cancer 1996;73(6):776-80.
1996: S Laohavinij; SR Wedge; Michael Lind; N Bailey; A Humphreys; M Proctor; F Chapman; D Simmons; A Oakley; L Robson; L Gumbrell; Gordon A Taylor; H D Thomas; Alan V Boddy; David R Newell; A Hilary Calvert
A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.
Investigational new drugs 1996;14(3):325-35.
1996: EJ Estlin; S Ablett; David R Newell; I J Lewis; Linda S Lashford; A D Pearson
Phase I trials in paediatric oncology--the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study Group.
Investigational new drugs 1996;14(1):23-32.
1996: S Ghazal-Aswad; A Hilary Calvert; David R Newell
A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve.
Cancer chemotherapy and pharmacology 1996;37(5):429-34.
1995: SR Wedge; S Laohavinij; Gordon A Taylor; Alan V Boddy; A Hilary Calvert; David R Newell
Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(12):1479-86.
1995: Michael J Millward; David R Newell; V Mummaneni; L N Igwemezie; K Balmanno; C J Charlton; L Gumbrell; Michael Lind; F Chapman; M Proctor
Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481).
European journal of cancer (Oxford, England : 1990) 1995;31A(13-14):2409-11.
1995: B Peng; Alan V Boddy; M Cole; Andrew D J Pearson; Etienne Chatelut; H Rubie; David R Newell
Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.
European journal of cancer (Oxford, England : 1990) 1995;31A(11):1804-10.
1995: Roger J Griffin; L C Pemberton; D Rhodes; C Bleasdale; K Bowman; A Hilary Calvert; Nicola J Curtin; Barbara W Durkacz; David R Newell; J K Porteous
Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP).
Anti-cancer drug design 1995;10(6):507-14.
1995: SR Wedge; S Laohavinij; Gordon A Taylor; David R Newell
Measurement of 5,10-dideaza-5,6,7,8-tetrahydrofolate (lometrexol) in human plasma and urine by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;663(2):327-35.
1995: Roger J Griffin; Nicola J Curtin; David R Newell; Bernard T Golding; Barbara W Durkacz; A Hilary Calvert
The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.
Biochimie 1995;77(6):408-22.
1995: S P Lowis; David R Newell; Andrew D J Pearson
Exposure and schedule dependency of etoposide in neuroblastoma and leukaemia cells in vitro.
European journal of cancer (Oxford, England : 1990) 1995;31A(4):622-6.
1995: Michael J Millward; David R Newell; Kally Yuen; J P Matthews; K Balmanno; C J Charlton; L Gumbrell; Michael Lind; F Chapman; M Proctor
Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.
Cancer chemotherapy and pharmacology 1995;37(1-2):161-7.
1994: P Bin; Alan V Boddy; Martin W English; Andrew D J Pearson; Lisa Price; Michael J Tilby; David R Newell
The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in paediatric patients: a review.
Anticancer research 1994;14(6A):2279-83.
1994: C E Arris; C Bleasdale; A Hilary Calvert; Nicola J Curtin; C Dalby; Bernard T Golding; Roger J Griffin; J M Lunn; G N Major; David R Newell
Probing the active site and mechanism of action of O6-methylguanine-DNA methyltransferase with substrate analogues (O6-substituted guanines).
Anti-cancer drug design 1994;9(5):401-8.
1994: J A Calvete; David R Newell; A F Wright; M S Rose
In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer.
Cancer research 1994;54(17):4684-90.
1994: David R Newell
Pharmacologically based phase I trials in cancer chemotherapy.
Hematology/oncology clinics of North America 1994;8(2):257-75.
1993: David R Newell; Andrew D J Pearson; K Balmanno; Lisa Price; RA Wyllie; Michael J Keir; A Hilary Calvert; I J Lewis; C R Pinkerton; M C Stevens
Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(12):2314-23.
1993: S P Lowis; Andrew D J Pearson; David R Newell; M Cole
Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.
Cancer research 1993;53(20):4881-9.
1993: J A Calvete; David R Newell; C J Charlton; A F Wright
Pharmacokinetic studies in mice with ICI D0490, a novel recombinant ricin A-chain immunotoxin.
British journal of cancer 1993;67(6):1310-5.
1993: Brenda J Foster; David R Newell; L A Gumbrell; K E Jenns; A Hilary Calvert
Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion.
British journal of cancer 1993;67(2):369-73.
1993: Brenda J Foster; David R Newell; J Carmichael; A L Harris; L A Gumbrell; M Jones; P M Goodard; A Hilary Calvert
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
British journal of cancer 1993;67(2):362-8.
1993: Michael J Tilby; David R Newell; C Viner; Peter J Selby; C J Dean
Application of a sensitive immunoassay to the study of DNA adducts formed in peripheral blood mononuclear cells of patients undergoing high-dose melphalan therapy.
European journal of cancer (Oxford, England : 1990) 1993;29A(5):681-6.
1993: J Cassidy; David R Newell; SR Wedge; Jeff Cummings
Pharmacokinetics of high molecular weight agents.
Cancer surveys 1993;17():315-41.
1992: David R Newell; R J Maxwell; Bernard T Golding
In vivo and ex vivo magnetic resonance spectroscopy as applied to pharmacokinetic studies with anticancer agents: a review.
NMR in biomedicine 1992;5(5):273-8.
1992: M A Graham; David R Newell; Brenda J Foster; L A Gumbrell; K E Jenns; A Hilary Calvert
Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.
Cancer research 1992;52(3):603-9.
1992: A Hilary Calvert; David R Newell; M E Gore
Future directions with carboplatin: can therapeutic monitoring, high-dose administration, and hematologic support with growth factors expand the spectrum compared with cisplatin?
Seminars in oncology 1992;19(1 Suppl 2):155-63.
1992: Brenda J Foster; David R Newell; M A Graham; L A Gumbrell; K E Jenns; S B Kaye; A Hilary Calvert
Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalation.
European journal of cancer (Oxford, England : 1990) 1992;28(2-3):463-9.
1991: D I Jodrell; David R Newell; S E Morgan; S Clinton; J P Bensted; L R Hughes; A Hilary Calvert
The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice.
British journal of cancer 1991;64(5):833-8.
1991: Ann L Jackman; David R Newell; W Gibson; D I Jodrell; G A Taylor; J A Bishop; L R Hughes; A Hilary Calvert
The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
Biochemical pharmacology 1991;42(10):1885-95.
1991: J L Mansi; A de Graeff; David R Newell; J Glaholm; D Button; Martin Leach; G Payne; I E Smith
A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
British journal of cancer 1991;64(3):593-7.
1991: David R Newell; J Mansi; J Hardy; D Button; K Jenns; I E Smith; R Picollo; B Catanese
The pharmacokinetics of oral lonidamine in breast and lung cancer patients.
Seminars in oncology 1991;18(2 Suppl 4):11-7.
1991: D I Jodrell; David R Newell; W Gibson; L R Hughes; A Hilary Calvert
The pharmacokinetics of the quinazoline antifolate ICI D 1694 in mice and rats.
Cancer chemotherapy and pharmacology 1991;28(5):331-8.
1990: David R Newell; R J Maxwell; G M Bisset; D I Jodrell; J R Griffiths
Pharmacokinetic studies with the antifolate C2-desamino-C2-methyl-N10-propargyl-2'-trifluoromethyl-5,8-dideazafolic acid (CB3988) in mice and rats using in vivo 19F-NMR spectroscopy.
British journal of cancer 1990;62(5):766-72.
1990: David R Newell
Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations.
British journal of cancer 1990;61(2):189-91.
1990: D J Kerr; C Lewis; B O'Neil; N Lawson; R G Blackie; David R Newell; F Boxall; J Cox; E M Rankin; Stanley B Kaye
The myelotoxicity of carboplatin is influenced by the time of its administration.
Hematological oncology 1990;8(1):59-63.
1989: A Hilary Calvert; David R Newell; L A Gumbrell; S O'Reilly; M Burnell; F E Boxall; Z H Siddik; I R Judson; M E Gore; E Wiltshaw
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(11):1748-56.
1989: Nicola J Curtin; David R Newell; Adrian L Harris
Modulation of dipyridamole action by alpha 1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole.
Biochemical pharmacology 1989;38(19):3281-8.
1989: M A Graham; David R Newell; A Hilary Calvert
Determination of the anthrapyrazole anticancer drug CI-941 in plasma and urine by solid-phase extraction and high-performance liquid chromatography.
Journal of chromatography 1989;491(1):253-61.
1989: T R Jones; T J Thornton; A Flinn; Ann L Jackman; David R Newell; A Hilary Calvert
Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency.
Journal of medicinal chemistry 1989;32(4):847-52.
1989: M A Graham; David R Newell; Brenda J Foster; A Hilary Calvert
The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.
Cancer chemotherapy and pharmacology 1989;23(1):8-14.
1989: David R Newell
Pharmacokinetic determinants of the activity and toxicity of antitumour agents.
Cancer surveys 1989;8(3):557-603.
1989: K R Harrap; Ann L Jackman; David R Newell; G A Taylor; L R Hughes; A Hilary Calvert
Thymidylate synthase: a target for anticancer drug design.
Advances in enzyme regulation 1989;29():161-79.
1989: David R Newell; R A Eeles; L A Gumbrell; F E Boxall; A Horwich; A Hilary Calvert
Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.
Cancer chemotherapy and pharmacology 1989;23(6):367-72.
1988: Ewa Sikora; Ann L Jackman; David R Newell; A Hilary Calvert
Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro.
Biochemical pharmacology 1988;37(21):4047-54.
1988: E Sikora; David R Newell; Ann L Jackman; A J Simmonds; T R Jones; A Hilary Calvert
Development of an assay for the estimation of N10-propargyl-5,8-dideazafolic acid polyglutamates in tumor cells.
Analytical biochemistry 1988;172(2):344-55.
1988: P A Speth; M E Gore; A J Pateman; David R Newell; J A Bishop; W J Ellis; J A Green; L A Gumbrell; P C Linssen; A Miller
Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone.
Cancer chemotherapy and pharmacology 1988;21(4):343-6.
1987: M A Graham; David R Newell; J Butler; B Hoey; L H Patterson
The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes. Inhibition of doxorubicin activation in vitro.
Biochemical pharmacology 1987;36(20):3345-51.
1987: David R Newell; Z H Siddik; L A Gumbrell; F E Boxall; M E Gore; I E Smith; A Hilary Calvert
Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin.
European journal of cancer & clinical oncology 1987;23(9):1399-405.
1987: Z H Siddik; David R Newell; F E Boxall; K R Harrap
The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
Biochemical pharmacology 1987;36(12):1925-32.
1987: A Hilary Calvert; David R Newell; Ann L Jackman; L A Gumbrell; Ewa Sikora; Barbara Grzelakowska-Sztabert; J A Bishop; I R Judson; S J Harland; K R Harrap
Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).
NCI monographs : a publication of the National Cancer Institute 1987;(5):213-8.